Skip to main content

Table 3 Most frequently reported treatment-emergent adverse events (≥ 5% of patients; safety population)

From: Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment: results of a 48-week open-label study

Adverse event N = 67 n (%) Safety population
Any adverse event 63 (94)
Vomiting 21 (31)
Nausea 19 (28)
Diarrhoea 17 (25)
Blood Bilirubin Increased 10 (15)
Fatigue 9 (13)
Hyperhidrosis 8 (12)
Insomnia 8 (12)
Influenza 7 (10)
Weight Decreased 7 (10)
Abdominal Pain 6 (9)
Abdominal Pain Upper 5 (7)
Constipation 5 (7)
Hyperbilirubinaemia 5 (7)
Sleep Disorder 5 (7)
Cheilitis 4 (6)
Gastritis 4 (6)
Headache 4 (6)
Hepatic Enzyme Increased 4 (6)
Lower Respiratory Tract Infection 4 (6)
Oral candidiasis 4 (6)